Physician profile
Scott Shepard
NPI 1659339844
$6,010.30
in general payments reported to CMS, 2019-2025
32 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $901 · 2022: $737 · 2023: $1,427 · 2024: $1,639 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,917 · Education: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.11 |
| Education | $454.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,081.15 | 2021-2025 | |
| Pfizer INC. | $826.37 | 2021-2025 | |
| Janssen Biotech, INC. | $723.10 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $407.93 | 2021-2024 | Ilumya, Blu-U, Odomzo |
| Lilly USA, LLC | $382.56 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Genzyme Corporation | $361.09 | 2021-2025 | |
| Leo Pharma INC. | $307.78 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Amgen INC. | $241.39 | 2021-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.28 | 2023-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $168.98 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $148.78 | 2021-2023 | Jublia |
| Regeneron Healthcare Solutions, INC. | $148.69 | 2021-2025 | Libtayo, Dupixent |
| Janssen Scientific Affairs, LLC | $119.29 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.08 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $78.30 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $73.43 | 2023-2024 | Idacio |
| Verrica Pharmaceuticals INC. | $68.75 | 2023-2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $68.46 | 2023-2025 | Zoryve |
| Convatec INC. | $58.87 | 2023-2025 | |
| Ucb, INC. | $57.61 | 2024 | Bimzelx |
| Allergan, INC. | $56.96 | 2022 | |
| Tela Bio, INC. | $51.49 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Galderma Laboratories, L.P. | $47.99 | 2024-2025 | Nemluvio, Aklief |
| Tempus Ai, INC | $47.87 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $30.35 | 2024 | Valchlor |
| Organon LLC | $29.43 | 2025 | Vtama |
| Botanix Sb INC | $25.98 | 2025 | Sofdra |
| Incyte Corporation | $20.80 | 2022 | |
| Organogenesis INC. | $19.03 | 2025 | Puraply Wound Matrix |
| Integra Lifesciences Corporation | $18.98 | 2022 | |
| Biofrontera INC. | $16.18 | 2022 | |
| Dermavant Sciences, INC. | $13.35 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Shepard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.